Related Experiment Videos
Current state of pneumococcal vaccines.
1Department of Vaccines, National Public Health Institute, Helsinki, Finland.
Scandinavian Journal of Immunology
|July 18, 2002
Summary
Streptococcus pneumoniae causes millions of childhood deaths annually. This review examines current and developing vaccines, highlighting the need for broader serotype coverage and infant efficacy in pneumococcal vaccines.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Streptococcus pneumoniae is a major global cause of childhood pneumonia and meningitis.
- Pneumococcal pneumonia causes over a million deaths in children under five annually.
- Emerging antibiotic resistance necessitates novel vaccine strategies.
Purpose of the Study:
- To review the current landscape of pneumococcal diseases and vaccines.
- To assess the limitations of existing vaccines, particularly in infants and low-resource settings.
- To highlight the development of new conjugate vaccines with expanded serotype coverage.
Main Methods:
- Literature review of existing pneumococcal vaccines.
- Analysis of serotype prevalence and vaccine efficacy data.
- Evaluation of ongoing clinical trials for novel pneumococcal vaccines.
Main Results:
- The 23-valent polysaccharide vaccine is effective in adults but not infants.
- The 7-valent conjugate vaccine shows infant efficacy but limited serotype coverage globally.
- Several 11-valent conjugate vaccines are in development, aiming for broader coverage and improved infant immunogenicity.
Conclusions:
- There is a critical need for cost-effective pneumococcal vaccines with extensive serotype coverage for all age groups.
- Conjugate vaccines are essential for inducing immunological memory in infants.
- Ongoing development of 11-valent vaccines shows promise in addressing global pneumococcal disease burden.